SkinHealth Systems Inc. (SKIN) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals: improved margins, reduced losses, and a strong cash position are positives, but declining revenues and device placements are concerning. The Q&A reveals cautious optimism about future growth and partnerships, but lacks concrete details. The guidance for 2026 suggests a challenging first half, with improvement expected later. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
Key Financial Performance
Net Sales $64.9 million, down 6.7% year-over-year. Reasons for the decline include macroeconomic factors such as tighter credit conditions, longer purchasing cycles, and increased competition.
Adjusted EBITDA $8.5 million, up 17% year-over-year. This increase reflects operational discipline and margin strength despite lower revenue.
Consumables Revenue $46.4 million, down 6.1% year-over-year. Approximately 2/3 of the drop was due to the transition of China to a distributor model last year, with additional impacts from timing-related variability in other regions.
Delivery Systems Revenue $18.5 million, down 8.3% year-over-year. Decline attributed to broader capital equipment pressure and lower device placements.
Active Installed Base 36,400 devices, up 4% year-over-year. Device churn declined 40% year-over-year, indicating improved provider retention and reactivation programs.
Adjusted Gross Margin 72.2%, up from 71.9% in the prior year. This improvement was achieved despite lower revenue.
GAAP Operating Expenses $46.2 million, down from $60.6 million in the prior year. Decline driven by lower headcount-related costs, reduced legal fees, and lower depreciation and amortization.
Net Loss $6.6 million, improved from a net loss of $10.1 million in the prior year. Improvement attributed to operational efficiencies and cost reductions.
Cash Position $204.4 million in cash, cash equivalents, and restricted cash. This reflects financial flexibility to address upcoming debt maturity and fund investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hydrafacial: Continues to be a central part of the company's strategy as a globally recognized specialty aesthetic treatment.
Keravive for Scalp Health: Planned relaunch with updated marketing, enhanced protocols, and improved integration into the Hydrafacial platform. Expected to address growing consumer focus on scalp health.
Next-generation Hydrafacial device: Development targeting a 2028 launch, aiming to deliver advancements in clinical outcomes and treatment experience.
China market transition: Shifted to a distributor model, impacting year-over-year consumables revenue comparisons.
Regional performance: Americas and EMEA regions experienced timing-related declines, while APAC showed growth in device orders due to distributor dynamics.
Adjusted EBITDA: Increased by 17% year-over-year to $8.5 million, reflecting operational discipline and margin strength.
Device churn: Declined by 40% year-over-year, indicating improved provider retention and reactivation programs.
Commercial execution improvements: Focused on structural sales processes, tighter pipeline management, and improved commercial leadership to address device placement softness.
Rebranding to Skin Health Systems: Reflects a shift towards operating as a leading medical device company with clinical rigor and commercial discipline.
Board additions: Three new independent directors with expertise in medtech, aesthetics, and global consumer brands were added to support the company's next phase.
Strategic partnerships: Exploring partnerships to integrate complementary technologies and expand treatment options.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Device placements below expectations: Device placements came below expectations during the quarter due to tighter credit conditions, longer purchasing cycles, and intensified competition. These structural headwinds are not one-time occurrences and are expected to persist.
Capital equipment demand constraints: Capital equipment demand continues to be constrained by tighter credit conditions and longer purchasing cycles, impacting revenue and growth potential.
Increased competition: Competition has intensified, providing providers with more choices and creating challenges for market share retention and growth.
Commercial execution challenges: Opportunities to improve commercial execution were identified, including the need for stronger sales discipline, better pipeline management, and improved account prioritization. These changes will take time to yield results.
Revenue outlook revision: The full-year revenue outlook was revised downward by approximately 2.5% due to continued softness in capital equipment demand and the time required for commercial initiatives to show results.
Consumables revenue decline: Consumables revenue declined 6.1% year-over-year, with a significant impact from the transition to a distributor model in China and timing-related variability in other regions.
Regional revenue declines: Revenue declines were observed in the Americas and EMEA regions, attributed to timing-related factors and broader capital equipment pressures.
China distributor transition impact: The transition to a distributor model in China continues to negatively impact year-over-year comparisons for consumables revenue.
Delayed commercial fixes: Commercial fixes, including leadership changes and structural sales process improvements, will take time to translate into improved trends, delaying potential revenue recovery.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook: The company revised its full-year revenue outlook to a range of $280 million to $295 million, down from the prior range of $285 million to $305 million. This reflects a reduction of approximately 2.5% or $7.5 million at the midpoint, due to continued softness in capital equipment demand and the time required for commercial execution improvements to take effect.
Adjusted EBITDA Guidance: Despite the revised revenue outlook, the company is maintaining its adjusted EBITDA guidance range of $35 million to $45 million, reflecting operational discipline and margin strength.
Q2 Revenue and EBITDA Expectations: For Q2, the company expects revenue of $72 million to $77 million and adjusted EBITDA of $11 million to $13 million.
Innovation Pipeline: The company is advancing its innovation pipeline with three key priorities: restructuring the booster portfolio, exploring strategic partnerships to expand treatment options, and developing the next-generation Hydrafacial device targeting a 2028 launch.
Keravive Relaunch: The company plans to relaunch its Keravive scalp health treatment later this quarter with updated marketing, enhanced protocols, and improved integration into the Hydrafacial platform, targeting the growing consumer focus on scalp health.
Next-Generation Hydrafacial Device: Development of the next-generation Hydrafacial device is underway, with a targeted launch in 2028. The device aims to deliver significant advancements in clinical outcomes and treatment experience, creating an upgrade opportunity for the installed base.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's strategy to address increasing competition and innovation in the market?
A:The company is focusing on its strengths, such as the Hydrafacial platform, and not competing purely on price. They aim to improve clinical outcomes, strengthen provider economics, fit naturally into treatment rooms, and ensure innovations are accretive to margin. They are also investing in the next-generation Hydrafacial and boosters, while making organizational changes to improve sales and management oversight.
Q:What are the company's plans for free cash flow and capital expenditures for the year?
A:The company expects modest free cash flow generation in the last three quarters of the year. Capital expenditures are projected to be $8 million to $10 million for the year, with $1.6 million to $1.7 million already spent in Q1. Working capital is expected to remain relatively flat year-over-year.
Q:What is the company's outlook for growth in the second half of the year?
A:The company expects gradual and sequential improvement in the second half of the year as commercial initiatives take effect. However, they anticipate returning to consistent growth in 2027, depending on the stabilization of the device business and the impact of new booster launches and strategic partnerships.
Q:What factors could influence the company's sales and EBITDA ranges?
A:Sales and EBITDA ranges depend on device sales trends, consumables demand, and execution of commercial initiatives. The company is focusing on improving utilization, booster attachment rates, and addressing tighter credit conditions and longer capital purchasing cycles.
Q:What are the company's plans for strategic partnerships?
A:The company is exploring partnerships on both the device and consumable sides, aiming to create an ecosystem of solutions. They are in late stages of diligence and feel encouraged by the progress.
Q:What caused the variability in consumables performance in certain regions?
A:The variability was due to timing-related factors, such as a strong Q4 promotion in 2025 and a large distributor order at the end of Q4 2025. Additionally, the transition to a distributor model in China impacted year-over-year comparisons.
Q:What is the company's strategy for the booster portfolio?
A:The company is restructuring the booster portfolio to focus on simplicity and impact, selecting boosters that deliver clear clinical outcomes. They plan to launch two new boosters this year, including the HydraScalp booster in Q2 and a clinically backed booster in Q4.
Q:How is the company addressing competition in the market?
A:The company is focusing on differentiation through clinical outcomes, provider economics, and consumer engagement. They aim to improve sales force training, messaging, and segmentation to compete effectively in a challenging market.
Q:What is the company's response to potential inflationary pressures?
A:The company has not observed significant inflationary impacts on input costs and does not expect inflation to materially affect adjusted EBITDA guidance.
Q:What details are available about the booster launching in Q4?
A:The booster is in late stages of development, and the company plans to provide updates closer to the launch time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the strategic partnerships and the booster launching in Q4, citing ongoing diligence and development stages. Additionally, they did not provide a clear timeline for when consumables performance in certain regions would normalize.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC device
Americas EMEA
Americas outperformance
China distributor
Consumables region
Delivery Systems
Dr experience
EMEA capital
EMEA distributor
GA headcount
Hydrafacial
Keravive scalp
Malha
RD
SkinHealth Systems
amortization
base system
condition
development
device placement
discipline
equipment demand
generation device
margin strength
maturity
objective
order
phase
platform
position
provider education
scalp health
softness
stage
technology
timing
today SkinHealth
training
year
SKIN Transcript
SkinHealth Systems Inc. (SKIN) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call summary presents mixed signals: improved margins, reduced losses, and a strong cash position are positives, but declining revenues and device placements are concerning. The Q&A reveals cautious optimism about future growth and partnerships, but lacks concrete details. The guidance for 2026 suggests a challenging first half, with improvement expected later. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement over the next two weeks.
The Beauty Health Company (SKIN) Q4 2025 Earnings Call Transcript
Positive3-13
The company has raised its revenue and EBITDA guidance, indicating strong financial metrics. Despite a challenging macroeconomic environment, the focus on controllable growth levers and operational discipline is promising. The Q&A reveals improved churn rates and strategic targeting of new demographics, which could enhance market penetration. While there are some uncertainties, such as the lack of specifics on new products, the overall sentiment is positive, with innovative strategies in place for future growth.
The Beauty Health Company (SKIN) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call reveals positive developments: increased revenue and EBITDA guidance, successful price hikes, and promising product launches. Although device sales face challenges, consumables show growth, and stabilization efforts are underway. The company's focus on innovation and strategic pricing, coupled with a positive market response to price increases, indicates a potential stock price uplift. However, management's lack of specific guidance for 2026 and ongoing macroeconomic pressures temper expectations, suggesting a moderate positive sentiment.
The Beauty Health Company (SKIN) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite exceeding Q1 revenue and EBITDA guidance, concerns about declining gross margins due to tariffs, increased R&D spending, and macroeconomic pressures, such as higher churn and ASP pressure, neutralize the positive impact. The optimistic guidance and strategic initiatives like new product launches and loyalty programs offer potential upside, but uncertainties in execution and financial health create a balanced outlook.
SKIN Slides
SKIN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
